Skeletal myoblast transplantation

No MAGIC bullet for ischemic cardiomyopathy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.

Original languageEnglish (US)
Pages (from-to)520-521
Number of pages2
JournalNature Clinical Practice Cardiovascular Medicine
Volume5
Issue number9
DOIs
StatePublished - Jul 30 2008

Fingerprint

Skeletal Myoblasts
Cardiomyopathies
Transplantation
Myoblasts
Myocardium
Stem Cells
Heart-Assist Devices
Ventricular Function
Heart Transplantation
Therapeutics
Stroke Volume
Cardiac Arrhythmias
Heart Failure
Bone Marrow
Placebos
Tissue Donors
Clinical Trials
Control Groups
Incidence

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{3b40753565674844aca32e059f3969e4,
title = "Skeletal myoblast transplantation: No MAGIC bullet for ischemic cardiomyopathy",
abstract = "Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.",
author = "Howard Eisen",
year = "2008",
month = "7",
day = "30",
doi = "10.1038/ncpcardio1299",
language = "English (US)",
volume = "5",
pages = "520--521",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "9",

}

Skeletal myoblast transplantation : No MAGIC bullet for ischemic cardiomyopathy. / Eisen, Howard.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 5, No. 9, 30.07.2008, p. 520-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Skeletal myoblast transplantation

T2 - No MAGIC bullet for ischemic cardiomyopathy

AU - Eisen, Howard

PY - 2008/7/30

Y1 - 2008/7/30

N2 - Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.

AB - Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.

UR - http://www.scopus.com/inward/record.url?scp=50649104813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649104813&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio1299

DO - 10.1038/ncpcardio1299

M3 - Article

VL - 5

SP - 520

EP - 521

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 9

ER -